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A 24-year-old female distance runner from Kenya immigrated to the United States in 
February 2010. In May 2011, 15 months later, she sought medical attention for right leg 
paresthesias and inguinal swelling. She reported increasing difficulty running, losing 
approximately 15% of her body weight, and experiencing intermittent fevers and sweats for 
several months. She withdrew from school because of extreme fatigue. Her white blood cell 
count was 2.1 (60% neutrophils, 32% eosinophils and 16% lymphocytes, 2% monocytes), 
hemoglobin level was 7.5, and platelet count was 121 000. A lymph node biopsy showed 
acid-fast bacilli (Figure 1) and grew Mycobacterium tuberculosis. Within a month of the 
tuberculosis diagnosis she presented with a mononeuritis multiplex, likely representing a 
second opportunistic infection (OI). Testing at that time indicated human immunodeficiency 
virus (HIV) infection, with a CD4 count of 84 cells/mm3 and viral load of 7.36 million 
copies/mL. She initiated standard antituberculosis therapy, followed by a boosted protease 
inhibitor antiretroviral regimen. Within 4 weeks, her symptoms improved, CD4 count 
increased to 174 cells/mm3, and viral load fell to 4150 copies/mL. However, 6 weeks after 
initiating therapy, her inguinal area became swollen and tender and her absolute eosinophilia 
persisted. A repeat lymph node biopsy revealed Wuchereria bancrofti (Figure 2), 
corresponding to positive filariasis serologies.
This case highlights several salient points. This patient did not get tested for HIV until she 
was very ill, despite her geographic origin from an area with high prevalence of HIV, her 
familiarity with the disease (ie, her brother is HIV positive), and suspecting that she was 
infected. The delay in HIV testing delayed her HIV diagnosis until OI onset, adversely 
affecting her schoolwork, running career, and social life, as well as her long-term prognosis. 
Further, Occam’s razor, as classically taught in internal medicine, does not apply to the 
differential diagnosis of persons with HIV-related immunodeficiency nor to immigrants and 
refugees from tropical settings.
Beginning 4 January 2010, HIV infection was removed from the list of inadmissible 
conditions for immigrants and refugees migrating to the United States [1]. Although it is still 
considered a “disease of public health concern,” immigrants and refugees are no longer 
required to undergo testing for HIV prior to arrival. The removal of this ban and the end of 
required HIV testing are viewed as steps forward in public policy, as they decrease HIV-
associated stigma and discrimination. However, as a result of this policy change, HIV-
positive immigrants and refugees are no longer identified prior to migration, challenging US 
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Identifying HIV infection early is cost effective, decreases associated morbidity, and 
provides a survival benefit [2, 3]. Additionally, evidence showing the efficacy of highly 
active antiretroviral therapy in increasing long-term survival has transitioned from an early 
era when HIV antiretroviral therapy was not initiated until the stage of advanced disease 
(CD4 <200 cells/mm3) toward an era of early intervention [4]. Recognizing this shift in best 
practices in HIV care, the Centers for Disease Control and Prevention (CDC) issued revised 
recommendations to include diagnostic HIV testing and opt-out HIV screening as a part of 
routine clinical care for all patients aged 13–64 years in all US healthcare settings [5]. In 
addition to being screened for HIV according to the revised recommendations, the CDC 
encourages screening of all refugees upon arrival, including those younger than 12 and older 
than 64 years of age [6].
One factor US clinicians and healthcare providers must consider in screening immigrants 
and refugees for HIV is the potential for epidemiologic differences in disease presentation 
compared with the general US population. For example, although tuberculosis is a less 
common OI for HIV-infected persons born in the United States, it remains the most common 
presenting OI for those with HIV worldwide, including African-born persons residing in the 
United States [7, 8]. The epidemiology of OIs in recently arrived immigrants and refugees 
tends to resemble that of the country or community where they lived before their arrival in 
the United States.
The case above illustrates a potential pitfall associated with the recent HIV testing policy 
change. If persons with HIV infection are not identified early, the likelihood increases that 
their HIV infection will be diagnosed late in disease or in conjunction with an OI. The later 
in the disease process HIV infection is identified, the worse the prognosis. To decrease 
disparities in this vulnerable population, early identification of HIV in immigrant and 
refugee populations is imperative.
Editorial comment. Although the discontinuation of routine screening for HIV in 
immigrants and refugees before they arrive in the United States represents a significant step 
forward in respecting human rights, it presents a new challenge to clinicians and the public 
health system to close the gap in early diagnosis. The CDC currently recommends screening 
all newly arriving refugees and any population with an HIV infection rate of >0.1%. 
Because early identification and initiation of therapy for HIV infection have been shown to 
significantly decrease disease progression and impact, including deaths, as well as decrease 
risk of transmission, the editors of this section highly recommend routine screening of all 
major groups of immigrants residing and arriving in the United States. In addition, every 
patient should be asked, “Where were you born?” and “Where have you traveled?” and 
further evaluation should be tailored on the basis of the epidemiology of diseases in the 
country of origin or travel. (M.C.)
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Lymph node stained with Ziehl-Neelsen, demonstrating acid fast bacilli (red). Photo 
courtesy of Bobbi Pritt, MD.
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Lower power (×40 original magnification) showing cross-sections of microfilariae within 
lymphatic channel. Photo courtesy of Bobbi Pritt, MD.
Taylor et al. Page 5
Clin Infect Dis. Author manuscript; available in PMC 2016 February 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
